Gut microbiome may influence how cancer patients respond to oral therapies, study suggests

September 29, 2020

LONDON, ONTARIO - A new study from Lawson Health Research Institute and Western University illustrates how the gut microbiome interacts with an oral medication in prostate cancer patients, suggesting bacteria in the gut play a role in treatment outcomes. The findings, Nature Communications, highlight how the drug abiraterone acetate is metabolized by bacteria in the gut to reduce harmful organisms while promoting those that fight cancer. The team suspects this is one of many examples of how the microbiome influences our response to medications.

"Research is beginning to uncover the ways in which the human microbiome influences cancer development, progression and treatment," explains Brendan Daisley, a PhD candidate at Western's Schulich School of Medicine & Dentistry who is conducting research at Lawson. "Our study highlights a key interaction between a cancer drug and the gut microbiome that results in beneficial organisms with anti-cancer properties."

Traditional prostate cancer therapies are designed to deprive the body of hormones called androgens, which are responsible for prostate cancer growth.

"Unfortunately, traditional androgen deprivation therapies are not always effective," explains Dr. Joseph Chin, Lawson Associate Scientist, Professor at Schulich Medicine & Dentistry and Urologist at London Health Sciences Centre (LHSC). "In those cases, alternative therapies are explored."

Abiraterone acetate is a highly effective therapy used in the treatment of prostate cancer that has been resistant to other treatments. While abiraterone acetate also works to reduce androgens in the body, it does so through a different mechanism and, unlike traditional therapies, it is taken orally.

"When drugs are taken orally, they make their way through the intestinal tract where they come into contact with billions of microorganisms," says Dr. Jeremy Burton, Lawson Scientist, Associate Professor at Schulich Medicine & Dentistry and lead researcher on the study. "While it's long been a mystery why abiraterone acetate is so effective, our team wondered if the gut microbiome plays a role."

The team's study included 68 prostate cancer patients from LHSC, including those being treated with abiraterone acetate and those being treated with traditional androgen deprivation therapies. The research team collected and analyzed patient stool samples, and conducted further experiments in their laboratory at St. Joseph's Health Care London.

They discovered that patients' gut microbiomes changed drastically after taking abiraterone acetate. Bacteria in the gut metabolized the drug leading to a significant increase in a bacterium called Akkermansia muciniphila. Referred to as a 'next-generation probiotic,' this bacterium's relevance has recently been explored in several large cancer studies. It's been shown to facilitate a better response to cancer immunotherapy drugs and it can elicit a wide range of other positive health benefits as well. The increase in Akkermansia muciniphila also led to an increased production of vitamin K2 which is known for anti-cancer properties that can inhibit tumour growth.

The team also observed the impact of androgen depletion on the microbiome. Both abiraterone acetate and traditional androgen deprivation therapies led to a decrease in organisms that utilize androgen.

"These findings clearly demonstrate that the gut microbiome is playing a role in treatment response," notes Dr. Burton.

The team hopes to further explore drug-microbiome interactions with a goal of harnessing the microbiome to improve treatment outcomes for a variety of diseases. In another study, they are exploring whether fecal microbiota transplants from a healthy donor can change the microbiome of melanoma patients to increase organisms like Akkermansia muciniphila and improve response to immunotherapy. They also plan to study whether analysis of a patient's microbiome can be used to predict their response to specific therapies.

"While more research is needed, we may one day be able to analyze a patient's microbiome to determine the best course of treatment or even influence the microbiome to improve outcomes," says Dr. Burton. "This could lead to a new frontier in personalized medicine."
The study was made possible through the generous support of The W. Garfield Weston Foundation, St. Joseph's Health Care Foundation and the Canadian Urologic Oncology Group.

MEDIA CONTACT: Robert DeLaet, Communications Consultant, Lawson Health Research Institute, t. 519.619.3872,


Lawson Health Research Institute is one of Canada's top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph's Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world.


Western University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.


The Schulich School of Medicine & Dentistry at Western University is one of Canada's preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.

Lawson Health Research Institute

Related Findings Articles from Brightsurf:

Skin findings described in patients with severe COVID-19
In this case series with four patients, the skin findings of livedo racemosa (skin discoloration) and retiform purpura are described in patients with severe COVID-19.

The latest findings on the MOSAiC floe
The New Siberian Islands were the birthplace of the MOSAiC floe: the sea ice in which the research vessel Polarstern is now drifting through the Arctic was formed off the coast of the archipelago, which separates the East Siberian Sea and the Laptev Sea to the north of Siberia, in December 2018.

Latest findings on bitter substances in coffee
Coffee is very popular around the world despite or perhaps because of its bitter taste.

Six-month follow-up appropriate for BI-RADS 3 findings on mammography
Women with mammographically detected breast lesions that are probably benign should have follow-up surveillance imaging at six months due to the small but not insignificant risk that the lesions are malignant, according to a new study.

Study looks at EVALI findings in teens
The first study to examine both chest X-ray and CT imaging findings in teenagers with electronic (e-)cigarette or vaping product use-associated lung injury (EVALI) was published today in the journal Radiology.

New findings on satiety signaling from intestine
A previously unknown mechanism that suppresses satiety signals from the small intestine is the main finding of a new study.

New findings on gut microbiome's interactions with GI diseases
A study from the Texas A&M College of Veterinary Medicine & Biomedical Sciences offers new insight on how the gut bacteria of dogs interact with a healthy vs. unhealthy GI tract, which could contribute to the development of new therapies for GI diseases in both dogs and humans.

New findings about mechanisms regulating brain inflammation
These new findings about mechanisms regulating brain inflammation open a new pathway in the field of neuroinflammation.

New research findings on dizziness of unknown cause
Many patients with functional dizziness look back on a long odyssey to numerous doctors, because no organic causes could be found.

Featured research findings from Nutrition 2019
Press materials are now available for Nutrition 2019, the flagship meeting of the American Society for Nutrition, to be held June 8-11, 2019 at the Baltimore Convention Center.

Read More: Findings News and Findings Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to